Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
1.
Ann Thorac Surg ; 114(5): 1542-1549, 2022 11.
Article in English | MEDLINE | ID: mdl-35963441

ABSTRACT

Reimbursement for cardiothoracic surgery continues to be threatened with enormous financial cuts ranging from 5% to 10% in recent years. In this policy perspective, we describe the history of reimbursement for cardiothoracic surgery, highlight areas in need of urgent reform, propose possible solutions that Congress and the Executive Branch may enact, and call cardiothoracic surgeons to action on this critical issue. Meaningful engagement of members of The Society of Thoracic Surgeons with their elected representatives is the only way to prevent these cuts.


Subject(s)
Specialties, Surgical , Thoracic Surgery , Aged , United States , Humans , Medicare
3.
J Clin Diagn Res ; 11(3): OC57-OC59, 2017 Mar.
Article in English | MEDLINE | ID: mdl-28511438

ABSTRACT

INTRODUCTION: The clinical relevance of surgical lung biopsy in Interstitial Lung Disease (ILD) is supported in the literature. Yet most reports reflect institutional or personal bias. AIM: To evaluate the validity of radiologic diagnosis and clinical impact of lung biopsy to help clarify which patient benefit most from biopsy. MATERIALS AND METHODS: We performed a retrospective analysis of a prospectively managed database. All patients who had a surgical lung biopsy for ILD within a period of four year (2009 to 2013) were included. Data included patient demographics, peri-operative variables and outcomes. Preoperative Computed Tomography (CT) imaging was reviewed by a thoracic radiologist blinded to the original report and pathologic information. RESULTS: A total of 47 patients were included. Lung tissue was obtained via a thoracoscopic approach in all but two that had mini-thoracotomy. Mean operating time was 51.1 minutes (18-123), median hospital stay was two days (1-18). Most (87.2%) of the patients were discharged within 72 hours. Thirty day mortality for elective surgery was 4.5% (2/44). Post-operative complications occurred in about one third of the patients. Complications in elective procedures included pneumothorax (10.4%), re-intubation (5.4%) and prolonged intubation (2.7%). Full concordance of radiographic diagnosis with the final diagnosis was significantly higher when reviewed by a cardiothoracic radiologist (60.5% vs. 21.3%). The preoperative clinical diagnosis was fully concordant with the final diagnosis in only 28.2% of cases. In 13.0% of patients the preoperative diagnosis was incorrect. Malignancy was the final diagnosis in two (4.3%) patients. In 51.1% of the patients, results of the biopsy did alter therapy. CONCLUSION: Diagnosis of specific ILD by a cardiothoracic radiologist is more specific and accurate and will probably lead to more appropriate therapy. Elective thoracoscopic surgical lung biopsy is a safe procedure, leads to a more accurate diagnosis of ILD and impacts therapy.

4.
Ann Thorac Surg ; 103(4): e327-e329, 2017 Apr.
Article in English | MEDLINE | ID: mdl-28359489

ABSTRACT

A 20-year-old woman presented with palpitations. Echocardiography demonstrated a left ventricular mass involving the posterolateral apical wall and protruding into the ventricular cavity. Evaluation with magnetic resonance imaging (MRI) suggested fatty consistency with all edges well defined except the medial, which was ill defined, raising concern for an invasive liposarcoma. Open core needle biopsy demonstrated mature adipocytes infiltrating the myocardium with extensive interstitial fibrosis. The diagnosis was left-dominant arrhythmogenic cardiomyopathy. Two-year MRI follow-up demonstrates no change in size. This case illustrates the use and limits of cardiac MRI and the value of open cardiac biopsy in diagnosis.


Subject(s)
Arrhythmias, Cardiac/etiology , Cardiomyopathies/complications , Heart Ventricles , Arrhythmias, Cardiac/diagnosis , Cardiomyopathies/diagnostic imaging , Cardiomyopathies/pathology , Female , Humans , Magnetic Resonance Imaging , Young Adult
6.
Ann Thorac Surg ; 98(3): 806-14, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25085561

ABSTRACT

BACKGROUND: National prosthesis use in active aortic valve infective endocarditis (IE) is unreported. Prosthesis usage and outcomes in patients undergoing an aortic valve operation with active IE was evaluated. METHODS: The Society of Thoracic Surgeons Adult Cardiac Surgery Database was used to identify patients with active IE who underwent an aortic valve operation from January 1, 2005, to June 30, 2011. All patients with active IE were included. Demographics, procedures, outcomes, and trends were analyzed. RESULTS: Of 11,560 patients who were identified as having active IE, 8,421 (73%) had no prior operations (primary) and 3,139 (27%) had a history of any prior cardiac operation (reoperative). Operations for primary vs reoperative patients included isolated replacement in 88.5% vs 58.7% and root replacement in 7.2% vs 29.9%. Major morbidity was 60.8% vs 68%, and the unadjusted mortality rate was 9.8% vs 21.1%. Over time, for primary operations, biologic valve use increased (57% to 67%), and mechanical and homograft valve use decreased (30% to 24% and 9% to 6%; p < 0.001). For reoperations, biologic valve use increased (38% to 52%), and mechanical and homograft use decreased (20% to 17% and 38% to 28%; p < 0.001). Homografts were used more often in reoperations (32% vs 7%). CONCLUSIONS: Morbidity and mortality rates death are high for operations for active IE. Biologic valves were increasingly used vs mechanical and homograft valves. Homograft valves were used more often in reoperative patients after any prior cardiac operation. The mortality rate varied among prosthesis groups but may be related to the severity of infection and type of procedure performed.


Subject(s)
Aortic Valve/surgery , Endocarditis/surgery , Heart Valve Diseases/surgery , Heart Valve Prosthesis , Adult , Cardiac Surgical Procedures , Databases, Factual , Female , Heart Valve Diseases/microbiology , Humans , Male , Middle Aged , Societies, Medical , Thoracic Surgery , Treatment Outcome
10.
Tex Heart Inst J ; 38(4): 431-2, 2011.
Article in English | MEDLINE | ID: mdl-21841877

ABSTRACT

Chylopericardium after cardiac surgery is rare, and there are few reports of its occurrence after aortic valve surgery. Chylous pericardial effusion 4 months after aortic valve replacement for endocarditis is highly unusual.Herein, we report the case of a 54-year-old man who had undergone bioprosthetic aortic valve replacement because of endocarditis and valvular dysfunction. Two months later, he underwent pericardiocentesis twice because of large pericardial effusions consisting of pinkish white fluid with predominant lymphocytes. Four months after valve replacement, he presented with recurrent effusion consistent with early tamponade, and a pericardial window was created. At surgery, 1,500 cc of milky white fluid was recovered, and the diagnosis of chylopericardium was made. Postoperative high-volume drainage prompted thoracic duct ligation, which was curative.


Subject(s)
Aortic Valve/surgery , Bioprosthesis , Chyle/metabolism , Heart Valve Prosthesis Implantation/adverse effects , Heart Valve Prosthesis Implantation/instrumentation , Heart Valve Prosthesis , Pericardial Effusion/etiology , Cardiac Tamponade/etiology , Humans , Ligation , Male , Middle Aged , Pericardial Effusion/diagnosis , Pericardial Effusion/metabolism , Pericardial Effusion/surgery , Pericardial Window Techniques , Pericardiocentesis , Prosthesis Design , Thoracic Duct/metabolism , Thoracic Duct/surgery , Time Factors , Treatment Outcome
14.
Ann Thorac Surg ; 85(6): 2161; author reply 2161, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18498855
16.
J Thorac Cardiovasc Surg ; 133(4): 1012-21, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17382644

ABSTRACT

OBJECTIVES: The appropriate index of prosthesis internal orifice size and its effect on operative mortality after aortic valve replacement are controversial. We examined the association between several relevant indices and patient size on operative mortality. Indices examined included projected in vivo effective orifice area and geometric orifice area, with patient size defined as body surface area. METHODS: A review of the Society of Thoracic Surgeons National Cardiac Database (2000-2004) yielded 48,722 patients who had isolated aortic valve replacement. This analysis is based on the cohort of 42,310 patients with the 8 most prevalent valve types with manufacturer's labeled sizes 19 mm through 29 mm. Multivariable logistic regression models were employed to determine the effects of body surface area, effective orifice area, geometric orifice area, and selected derived indices (eg, effective orifice area/body surface area) on risk-adjusted operative mortality. RESULTS: In separate multivariable models, effective orifice area and geometric orifice area were both inversely correlated with operative mortality. However, an unanticipated finding was that with either effective orifice area or geometric orifice area held constant, body surface area was significantly and inversely correlated with operative mortality. When patients were stratified by effective orifice area, geometric orifice area, or manufacturer's labeled valve size and type, elevations in body surface area were associated with a decrease rather than an increase in operative mortality. CONCLUSIONS: Prostheses with small geometric orifice area or small effective orifice area are associated with increased operative mortality after isolated aortic valve replacement. Even for valves with small effective orifice area, however, mortality decreases as body surface area increases. With respect to operative mortality, therefore, our results do not support using arbitrary cutoff values of effective orifice area/body surface area to determine the valve to utilize in a given patient.


Subject(s)
Aortic Valve/surgery , Body Surface Area , Heart Valve Prosthesis Implantation/instrumentation , Heart Valve Prosthesis Implantation/mortality , Heart Valve Prosthesis , Adult , Aged , Aged, 80 and over , Female , Heart Valve Diseases/surgery , Humans , Male , Middle Aged , Prosthesis Design
17.
Ann Thorac Surg ; 83(3): 1002-6, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17307448

ABSTRACT

BACKGROUND: Use of both internal thoracic arteries has been limited in diabetic patients fearing an increased incidence of deep sternal wound infection. We analyzed this concern by querying The Society of Thoracic Surgeons Database. METHODS: Diabetic patients who had isolated coronary artery bypass graft surgery during 2002 to 2004 were included if they had no prior bypass surgery, two or more distal bypasses, and a left internal thoracic artery bypass. Group B (both internal thoracic arteries) was compared with group L (left internal thoracic artery only). RESULTS: The incidence of deep sternal wound infection for all patients undergoing isolated first-time bypass surgery was less than 1%. Of these, 120,793 patients met criteria for inclusion: group B, 1.4% (1732); and group L, 98.6% (119,061). Group B had a higher crude (unadjusted) deep sternal wound infection rate of 2.8% (49) versus 1.7% (1969; p = 0.0005) in group L, with an estimated odds ratio of 2.23 (95% confidence interval, 1.69 to 2.96). Group B had a similar crude mortality rate of 1.7% (30) versus 2.3% (2785; p = NS) in group L, with an estimated odds ratio of 1.110 (95% CI, 0.78 to 1.59; p = NS). Patients in group B were younger, mostly male, had a lower serum creatinine level, and were more often current smokers; less commonly, they were insulin dependent, diagnosed with pulmonary or vascular disease, or on dialysis. Other risk factors for deep sternal would infection included female gender, insulin dependence, peripheral vascular disease, recent infarction, body mass index exceeding 35 kg/m2, and use of blood products. CONCLUSIONS: There is a significant increase in the incidence of deep sternal would infection in diabetic patients. This is further increased with the use of both internal thoracic arteries with no apparent short-term mortality difference.


Subject(s)
Coronary Artery Bypass/adverse effects , Coronary Disease/surgery , Diabetic Angiopathies/surgery , Mammary Arteries/transplantation , Sternum/surgery , Surgical Wound Infection/etiology , Aged , Coronary Artery Bypass/methods , Coronary Artery Bypass/mortality , Diabetes Mellitus, Type 1 , Female , Humans , Incidence , Male , Middle Aged , Risk Factors , Surgical Wound Infection/epidemiology
19.
Future Cardiol ; 1(4): 419-20, 2005 Jul.
Article in English | MEDLINE | ID: mdl-19804140
20.
Crit Care Med ; 32(6): 1327-31, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15187515

ABSTRACT

OBJECTIVE: To determine whether pressor doses of vasopressin impair organ blood flow in endotoxic shock. DESIGN: Graded doses of vasopressin or phenylephrine, starting at the clinically recommended doses for pressure support in septic shock, were intravenously infused during endotoxic shock. SETTING: University hospital surgical research laboratory. SUBJECTS: Twelve random-bred female Yorkshire pigs. INTERVENTIONS: We measured mean arterial pressure, cardiac output, heart rate, pulmonary artery occlusion pressure, and carotid, mesenteric, renal, and iliac blood flows. MEASUREMENTS AND MAIN RESULTS: Low doses of vasopressin (typically used in the clinical management of septic shock) raised arterial pressure by increasing systemic vascular resistance without a significant preferential effect in the circulations measured. However, moderately greater doses of vasopressin had a very heterogeneous vasoconstrictor action; although there was no significant vasoconstriction in the carotid and iliac circulations, mesenteric and renal blood flows decreased markedly. Furthermore, at pressor doses vasopressin improved cerebral perfusion. CONCLUSIONS: The vasoconstrictor action of exogenous low-dose vasopressin in endotoxic shock does not impair blood flow to any of the vascular beds examined. However, moderately higher doses of vasopressin may induce ischemia in the mesenteric and renal circulations. The data indicate that the safe dose range for exogenous vasopressin in septic shock is narrow and support the current practice of fixed low-dose administration, generally 0.04 units/min and in no case exceeding 0.1 units/min.


Subject(s)
Shock, Septic/physiopathology , Vasoconstriction/drug effects , Vasoconstrictor Agents/pharmacology , Vasopressins/pharmacology , Animals , Blood Pressure/drug effects , Cardiac Output/drug effects , Carotid Arteries/drug effects , Cerebrovascular Circulation/drug effects , Female , Heart Rate/drug effects , Iliac Artery/drug effects , Mesenteric Arteries/drug effects , Phenylephrine/pharmacology , Pulmonary Artery/drug effects , Renal Artery/drug effects , Swine , Vasoconstrictor Agents/administration & dosage , Vasopressins/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...